These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. How to minimize missing those subjects with high 2HR plasma glucose but 'normal' fasting plasma glucose levels? Ko GT; Cockram CS; Chan JC J Med; 2001; 32(1-2):53-65. PubMed ID: 11321888 [TBL] [Abstract][Full Text] [Related]
11. Impaired glucose tolerance, impaired fasting glycaemia and cardiovascular risk. Sanusi H Acta Med Indones; 2004; 36(1):36-41. PubMed ID: 15673935 [TBL] [Abstract][Full Text] [Related]
12. Impaired fasting glucose in hypertensive patients: prevalence and cross-sectional analysis of associations with cardiovascular disease. Tziomalos K; Spanou M; Baltatzi M; Efthymiou E; Psianou K; Papastergiou N; Iliadis F; Didangelos TP; Savopoulos C; Hatzitolios AI Diabetes Technol Ther; 2013 Jun; 15(6):475-80. PubMed ID: 23544673 [TBL] [Abstract][Full Text] [Related]
13. From metabolic normality to cardiometabolic risk factors in subjects with obesity. Bobbioni-Harsch E; Pataky Z; Makoundou V; Laville M; Disse E; Anderwald C; Konrad T; Golay A; Obesity (Silver Spring); 2012 Oct; 20(10):2063-9. PubMed ID: 22421925 [TBL] [Abstract][Full Text] [Related]
14. [Clinical and metabolic features of subjects with glucose intolerance and high fasting glucose levels]. Arteaga Llona A; Pollak F; Robres L; Velasco N Rev Med Chil; 2009 Feb; 137(2):193-9. PubMed ID: 19543640 [TBL] [Abstract][Full Text] [Related]
15. The association between pulse wave velocity and metabolic syndrome and adiponectin in patients with impaired fasting glucose: cardiovascular risks and adiponectin in IFG. Nam JS; Park JS; Cho MH; Jee SH; Lee HS; Ahn CW; Lowe WL; Kim KR Diabetes Res Clin Pract; 2009 May; 84(2):145-51. PubMed ID: 19261346 [TBL] [Abstract][Full Text] [Related]
16. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Tominaga M; Eguchi H; Manaka H; Igarashi K; Kato T; Sekikawa A Diabetes Care; 1999 Jun; 22(6):920-4. PubMed ID: 10372242 [TBL] [Abstract][Full Text] [Related]
17. High prevalence of neuropathy in patients with impaired 60-minute oral glucose tolerance test but normal fasting and 120-minute glucose levels. Sahin M; Karatas M; Sahin M; Ertugrul D; Kulaksizoğlu M; Dogruk A; Gokcel A; Tutuncu NB; Guvener ND; Kutlu M Minerva Endocrinol; 2008 Dec; 33(4):289-96. PubMed ID: 18923366 [TBL] [Abstract][Full Text] [Related]
18. Blood glucose is associated with chronic kidney disease in subjects with impaired glucose tolerance, but not in those with impaired fasting glucose. Wang C; Song J; Sun Y; Hou X; Chen L J Diabetes; 2014 Nov; 6(6):574-6. PubMed ID: 24889516 [No Abstract] [Full Text] [Related]
19. Serum sialic acid, a possible cardiovascular risk factor is not increased in Fijian Melanesians with impaired glucose tolerance or impaired fasting glucose. Crook MA; Goldsmith L; Ameerally P; Lumb P; Singh N; Miell J; Russell-Jones D Ann Clin Biochem; 2002 Nov; 39(Pt 6):606-8. PubMed ID: 12564845 [TBL] [Abstract][Full Text] [Related]
20. Metabolic and cardiovascular risk factors in subjects with impaired fasting glucose: the 100 versus 110 mg/dL threshold. Andreozzi F; Succurro E; Mancuso MR; Perticone M; Sciacqua A; Perticone F; Sesti G Diabetes Metab Res Rev; 2007 Oct; 23(7):547-50. PubMed ID: 17311284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]